Novartis Pharmaceuticals – AfricaNewsAnalysis

Neues Malaria-Target mit dem Potenzial zur Prophylaxe, Hemmung und Behandlung verschiedener Stadien des Malarialebenszyklus identifiziert

28/11/2013 ANA 0

Wissenschaftler von Novartis haben ein neues Wirkstoff-Target zur Behandlung von Malaria gefunden. Ihrer Entdeckung zufolge, die in Nature online publiziert wurde,[2] fungiert die Phosphatidylinositol-4-Kinase (PfPI4K) als Target für Imidazopyrazine, eine neuartige, experimentelle Antimalaria-Wirkstoffklasse, welche die […]

Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV

07/10/2013 ANA 0

Novartis announced recently results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis[1]. Enbrel is a current standard-of-care anti-TNF medication […]

New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients

07/10/2013 ANA 0

Novartis recently announced new data indicating that continued treatment with Gilenya® (fingolimod) led to a reduction in brain volume loss in patients with relapsing forms of multiple sclerosis (MS), and was associated with a higher […]

New data for Novartis drug Lucentis® reinforces transformational efficacy and well-established safety profile across four indications

01/10/2013 ANA 0

New clinical and real world data for Lucentis® (ranibizumab) presented in over 40 abstracts at this week’s EURETINA congress confirm its transformational and well-established safety profile in four retinal diseases. Designed for intraocular use, Lucentis […]

Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro® Breezhaler® (QVA149)

08/09/2013 ANA 0

Novartis announced today new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 – indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in […]

Novartis receives positive CHMP opinion for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis

26/07/2013 ANA 0

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Ilaris® (canakinumab) in the treatment of active […]

Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel® in head-to-head Phase III psoriasis study

11/07/2013 ANA 0

Novartis announced July 8 top-line results from the head-to-head Phase III psoriasis study which showed the superiority of secukinumab (AIN457) in clearing skin to Enbrel®* (etanercept), an anti-tumor necrosis factor (anti-TNF) therapy. In addition, secukinumab […]